Targeting the immunometabolism interface: A novel strategy for IPF therapy

Area of Science:

• Pulmonary Medicine
• Immunology
• Metabolic Research

Background:

• Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease marked by tissue remodeling and fibrosis.
• Emerging research highlights the crucial role of immunometabolism in IPF pathogenesis.
• Dysregulated metabolic pathways significantly impact immune responses and fibrotic progression in IPF.

Purpose of the Study:

• To synthesize current findings on immunometabolism interactions in IPF.
• To emphasize the potential of metabolic reprogramming and immune modulation as novel therapeutic strategies.
• To identify challenges and future research directions for IPF treatment.

Main Methods:

• Review of current scientific literature on IPF, immunometabolism, and related molecular pathways.
• Analysis of key regulators like PPARG, SPP1, and signaling pathways (mTOR, AMPK, HIF-1α).
• Synthesis of evidence linking metabolic dysregulation to immune cell function and fibrosis.

Main Results:

• Key molecular regulators (PPARG, SPP1) and signaling pathways (mTOR, AMPK, HIF-1α) orchestrate immune cell polarization, fibroblast activation, and ECM production in IPF.
• Immunometabolism dysregulation is central to IPF pathogenesis, modulating immune responses and fibrotic progression.
• Therapeutic targets at the intersection of metabolism and immunity are promising for IPF treatment.

Conclusions:

• Metabolic reprogramming and immune modulation represent novel therapeutic avenues for IPF.
• Significant challenges remain in understanding precise mechanisms and translating preclinical findings into clinical practice.
• Future research should focus on biomarkers, target refinement, and personalized therapies to improve IPF outcomes.